Amarin Corp Plc (AMRN)

[jessellivermore]

Re RRR levels....

In addition to the Primary Endpoint (MACE)...There is at least 30 other parameters being compiled...

For the Primary Endpoint the RRR is very unlikely to be under 20% based on JELIS experience where the RRR of the PE in the secondary prevention group was about 20% and the component SEs were also about 20%...Going on the premise that CVD risk is inversely proportional to the EPA/AA ration..(this was seen to be the case across the entire JELIS study...and held across the board regardless of the arm patients were in).

The additional 1.8 gms/day in JELIS changed the EPA ratio from about 0.7 to 1.4 this doubled the EPA/AA ratio resulting in a 20% reduction...In R-I the control arm should have an estimated EPA/AA ratio of about 0.07 and 4gms EPA/day should increase this to about 0.5..roughly a seven fold increase..So unless the EPA/AA ratio hypothesis is completely wrong.. It is very very unlikely we would see RRRs less than 25% in PE and other component SEs....

":>) JL